new glp 1 drugs From 'companion foods' to 'Nature's Ozempic.' Big food & GLP-1 Until now, they were largely

Source: #GLP1 #MentalHealth #MetabolicHealth #Longevity #HealthLongevitySecrets GLP-1s are changing obesity care but nutrition may be the silent side effect. As Jorge Urbina and colleagues highlight in a 2026 Clinical Obesity narrative review, GLP-1 receptor agonists (e.g., semaglutide, liraglutide, tirzepatide) can predispose some patients to micronutrient and nutritional deficienciesvia appetite suppression, delayed gastric emptying, and altered intake/absorption

Terushkin says

Current Opinion in Pediatrics , 36(4), 449-455

Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery

The global anti-obesity drug market is experiencing significant opportunities due to the growing prevalence of obesity and an increasing demand for safer, more effective, and patient-friendly treatments

[DOI] [PMC free article] [PubMed] [Google Scholar] 64.Hashempour A., Hooshmand S., Tabesh M.R., Alizadeh Z